NOVAVAX INC (NVAX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6700024010
NOVAVAX INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.12 bn USD |
| Gross profit | 1.05 bn USD |
| Operating income | 452.80 m USD |
| EBIT | 435.21 m USD |
| Net income | 440.30 m USD |
| Diluted EPS – continuing operations | 2.58 USD |
Full history since 1996, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NOVAVAX INC
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
More stocks
- Guangdong Mingyang Electric Co. Ltd. A (301291.SZ)
- Pagaya Technologies Ltd. (PGY)
- JPMorgan Japanese Investment Trust PLC (JFJ.L)
- ShenZhen Yitoa Intelligent Control Co Ltd (300131.SZ)
- Strategic Education, Inc. (STRA)
- Volution Group PLC (FAN.L)
- Dayamitra Telekomunikasi PT (MTEL.JK)
- Trust Alliance Information Development Inc Ltd Shanghai (300469.SZ)
- Genesis Energy Ltd (GNE.AX)
- Altius Minerals Corp (ALS.TO)
- HOPE BANCORP INC (HOPE)
- OCEANFIRST FINANCIAL CORP (OCFC)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.